Drug intelligence / Profile preview

26ND02

Development stage: Preclinical
Lead developer: HK inno.N Corporation
Modality: Small Molecules

Overview

26ND02 is a small molecule drug candidate currently in the discovery stage of development by HK inno.N (formerly CJ HealthCare). The drug is being developed for the treatment of cachexia, a complex metabolic syndrome characterized by progressive loss of body weight, muscle atrophy, and fatigue, often associated with underlying chronic diseases such as cancer or heart failure. As of early 2026, the specific biological target and mechanism of action for 26ND02 have not been publicly disclosed by the developer.

Beyond the preview

Go deeper on 26ND02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 26ND02.

Explore the full profile